Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus LOVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus LOVASTATIN.
ATORVASTATIN CALCIUM vs LOVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
10-80 mg orally once daily in the evening, starting at 10-20 mg once daily; maximum dose 80 mg/day.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
Clinical Note
moderateLovastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Resveratrol
"The serum concentration of Resveratrol can be increased when it is combined with Lovastatin."
Clinical Note
moderateLovastatin + Betamethasone
Terminal elimination half-life: 1.5–2 hours for lovastatin acid; clinical context: short half-life supports evening dosing to maximize HMG-CoA reductase inhibition during peak cholesterol synthesis.
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Renal: 10% (as metabolites); Fecal: 83% (primarily as metabolites); Biliary: minor; <5% excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Betamethasone can be increased when it is combined with Lovastatin."